ABSTRACT
Myelodysplastic syndromes (MDS) are very heterogeneous in terms of their cytomorphology, clinical features, and survival. 1 In 1982, the French-American-British (FAB) classification for the diagnosis of MDS was proposed, 2 and the current World Health Organization (WHO) classification 3 was proposed in 2008. The chapter on refractory cytopenia with unilineage dysplasia of the WHO classification described that "the type of cytopenia in the majority of cases will correspond to the type of dysplasia, e.g. anemia and erythroid dysplasia." 4 Although many groups have reported the cytomorphologic findings of MDS, to our knowledge a detailed analysis of the relationship between dysplastic lineage and the type of cytopenia has not been completely studied. Therefore, the correlation between dysplastic lineage and the type of cytopenia is unclear. Patients with MDS who do not exhibit a correlation between dysplastic lineage and the type of Upon completion of this activity you will be able to:
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Questions appear on p 277. Exam is located at www.ascp.org/ajcpcme. cytopenia certainly exist. For example, MDS associated with isolated del(5q) (5q-syndrome) shows remarkable dysplastic features of megakaryocytic lineage in bone marrow (BM). However, the platelet counts of patients with 5q-syndrome do not usually decrease. 3 Previously, we reported a detailed cytomorphologic analysis of refractory anemia according to the FAB classification (FAB-RA). 5 Using this data set, we analyzed the relationship between dysplastic lineage and cell count in the present study.
Materials and Methods

Patients
The data set of Japanese patients from our previous study 5 was used for this study. Patients included those with primary MDS excluding refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia and ringed sideroblasts, refractory anemia with excess of blasts (RAEB), or 5q-syndrome according to WHO classification (version 3). 6 Therefore, all patients in this study had FAB-RA except those with 5q-syndrome. Patients were diagnosed at the Saitama Medical University Hospital, Nagasaki University Hospital, or affiliated hospitals between April 1976 and January 2002. BM cellularity and fibrosis were evaluated by BM trephine biopsy and/or clot section. Patients with BM fibrosis were excluded, because the accuracy of morphologic evaluations might be not reliable owing to the few BM cells of the films. Disorders other than MDS (eg, aplastic anemia, paroxysmal nocturnal hemoglobinuria, megaloblastic anemia, autoimmune hemolytic anemia, anemia of chronic disorders, large granular lymphocytic leukemia, hairy cell leukemia, chronic liver disorders, and hypersplenism) were excluded. Patients who had previous therapy (antineoplastic drugs and/ or ionizing radiation) or other prior hematologic disease also were excluded from the study. This study was approved by the Institutional Review Board of Saitama International Medical Center, Saitama Medical University. Retrospective analysis was performed in 100 Japanese patients. Age, sex, and cytogenetic findings of patients at diagnosis are summarized in ❚Table 1❚.
Cytomorphologic Study
Microscopic examinations were performed using standard methods (BM Wright-Giemsa [WG] In the present study, we analyzed the correlation between dysplasia and cell count using the data set of our previous morphologic study, in which we performed a detailed cytomorphologic analysis. We limited dysplasias to only dysplasias described in the WHO classification (version 3) 6 as follows. Dysplasias of the nucleus in erythroid lineage cells were defined as having budding, bridging, internuclear, karyorrhexis, multinuclearity, or megaloblastoid changes. Dysplasias of the cytoplasm in erythroid lineage cells were defined as having ring sideroblasts, vacuolization, or PAS positivity (diffuse or granular). With regard to granulocytes, dysplasias were defined as having the following characteristics: small size, nuclear hyposegmented mature neutrophils (Pelger), hypersegmentation, hypogranularity, or pseudoChédiak-Higashi granules. Dysplasias of megakaryocytes were defined as having micromegakaryocytes (mMgk), nonlobulated nuclei, or multiple widely separated nuclei. A minimum of 25 megakaryocytes, 200 erythroblasts, and 200 neutrophils in BM were examined in each patient. The cutoff levels for dyserythropoiesis (dys E) and dysgranulopoiesis (dys G) were defined as 10% according to the WHO classification. 6 Dysmegakaryopoiesis (dys Mgk) was evaluated with 2 cutoff levels: 10% according to the WHO classification or 40% according to data previously reported from the German group. 7, 8 Since the accuracy of the quantitative evaluation of dysmegakaryopoiesis might be not reliable when there are few megakaryocytes to examine, we excluded patients who did not have at least 25 examined megakaryocytes from the morphologic evaluation of the megakaryocytic lineage. In our previous study, we reported that 2 distinct dysplastic changes, Pelger and mMgk ❚Image 1❚, had negative prognostic impacts. Therefore, Pelger and mMgk were also evaluated. We defined hyposegmented mature neutrophils with strikingly clumpy chromatin as "Pelger" and mononucleated or binucleated megakaryocytes with a size equal to or smaller than promyelocytes as "mMgk." Positivity for Pelger (Pelger+) was defined as the presence of 10% or more Pelger among 200 mature neutrophils. Positivity for mMgk (mMgk+) was defined as the presence of 10% or more mMgk among 25 or more megakaryocytes. Patients with decreased megakaryocytes were assessed as being negative for mMgk (mMgk-). 
Definition of Cytopenias
To analyze the relationship between dysplasia and cytopenia, we compared hemoglobin (Hb) concentrations, absolute neutrophil counts (ANCs), platelet counts, and types of cytopenia. The definitions of cytopenias were as follows: Hb concentration less than 10 g/dL, ANC less than 1.8 × 10 9 /L, and platelet count less than 100 × 10 9 /L. 3
Statistical Analysis
Continuous data were compared using the nonparametric Mann-Whitney test, and proportions were compared using the c 2 test. A 2-sided P value of less than .05 was considered statistically significant.
Results
Cytomorphologic Study
In our previous data set, we evaluated suitable BM preparations for the detailed assessments of myelodysplasia. 5 Results of morphologic analysis are shown in ❚Table 2❚ and ❚Table 3❚. Some BM preparations could not be examined in detail. In particular, observing the granules of neutrophils was difficult due to the poor staining condition of the films. Four cases could not be evaluated for the frequency of dys G, and 1 case could not be evaluated for the frequency of Pelger. Nineteen patients showed decreased megakaryocytes. Therefore, 
Relationship Between Dysplasia and Cell Count
Results of the relationship between dysplasia and cell count are shown in Tables 2 and 3 . There was no relationship between the presence of dys G of 10% or more and ANC. Similarly, Pelger+ was not related to ANC. Interestingly, platelet counts of patients with dys Mgk of 10% or more tended to be higher than those of patients without dys Mgk of 10% or more (P = .08). Moreover, in patients with dys Mgk of 40% or more, this difference in platelet counts was significant (dys Mgk ≥40% vs <40%, P = .02). In particular, in patients with mMgk+, the sign became even clearer (P = .004). In patients with dys Mgk of 40% or more, the platelet count of those with mMgk+ was not different from those without mMgk+ (P = .47). Of the 19 patients who showed unilineage cytopenia, only 2 had unilineage dysplasia. However, dysplastic lineages were different from the lineages of cytopenia ❚Table 4❚. Of the 11 patients who showed unilineage dysplasia, only 2 had unilineage cytopenia. However, lineages of cytopenia were different from dysplastic lineages ❚Table 5❚.
Discussion
Generally, it seems that cytopenias correspond to dysplastic lineage, but this has not been studied completely. Increases in blasts in BM may reduce blood cell counts due to hematopoietic injury. Patients with 5q-syndrome show anemia due to erythroid hypoplasia. 9, 10 Increases in blasts or the existence of del(5q) may influence the decrease in cell count. To examine the correct relationship between dysplastic lineage and cell count, we excluded patients with RAEB or 5q-syndrome. Our previous data set used for the present study also does not include these cases. Therefore, it seems that this data set is suitable for the purpose of the present study.
Recently, it was reported that there was no clear correlation between the presence of any distinct dysplastic sign and cell counts in patients with MDS. 11 In the present study, we could not find any correlation between the presence of dys G of 10% or more and ANC. Low ANC cannot be directly explained by the presence of dys G. This result suggests that dysplastic features in granulocytic lineage may be unrelated to ineffective hematopoiesis explained by apoptosis. Interestingly, the platelet count of patients with dys Mgk was higher than that of patients without dys Mgk (dys Mgk ≥10% vs <10%, P = .08; dys Mgk ≥40% vs <40%, P = .02; mMgk+ vs mMgk-, P = .004). Although patients with 5q-syndrome show remarkable dysplastic features of megakaryocytic lineage in BM, their platelet counts are usually normal or increased. Thrombocytopenia is uncommon. 3, 9, 10 In the present study, a correlation between dys Mgk and platelet counts was similar to the characteristics of 5q-syndrome. These findings suggest that dys Mgk is not related to a direct sign of apoptosis, at least in the megakaryocytic lineage. In addition, we analyzed the correlation between the frequency of dys Mgk and the number of megakaryocytes. Evaluation of the megakaryocyte count was performed using specimens of the BM trephine biopsy and/or clot section. Of the 38 patients with dys Mgk of 40% or more, 21 (55%), 10 (26%), and 7 (17%) had increased, normal, and decreased megakaryocyte counts, respectively. In patients with dys Mgk of 40% or more, megakaryocyte counts tended to increase. In contrast, of the 43 patients without dys Mgk of 40% or more, 5 (12%), 17 (40%), and 21 (48%) had increased, normal, and decreased megakaryocyte counts, respectively. In patients without dys Mgk of 40% or more, megakaryocyte counts did not tend to increase. This finding was similar to a correlation between megakaryocyte count and mMgk. In 12 patients with mMgk+, 9 (75%), 3 (25%), and 0 had increased, normal, and decreased megakaryocyte counts, respectively. In patients with mMgk+, megakaryocyte counts tended to increase. In contrast, of the 88 patients without dys mMgk+, 17 (19%), 24 (27%), and 47 (53%) had increased, normal, and decreased megakaryocyte counts, respectively. In patients without mMgk+, megakaryocyte counts did not tend to increase. Increases in megakaryocyte counts may be a reason for the increase in platelet counts in patients with dys Mgk of 40% or more or mMgk+. Only 6 patients had hypoplastic BM. There was no significant difference in Hb concentrations between hypoplastic BM and nonhypoplastic BM patients (P = .51). Similarly, there was no significant difference in ANC between the 2 groups (P = .44). Nineteen patients had decreased megakaryocytes. Interestingly, the platelet count of patients with decreased megakaryocytes (median, 18 × 10 9 /L) was significantly lower than that of patients without decreased megakaryocytes (median, 48 × 10 9 /L) (P < .001). This finding is similar to the mechanism of thrombocytopenia in patients with aplastic anemia. It seems that the presence of decreased megakaryocytes may be associated with the presence of thrombocytopenia even in patients with MDS.
We could not find a correlation between dysplastic lineage and low cell counts. Low ANC cannot be explained by the presence of dys G. The platelet count of patients with dys Mgk was higher than that of patients without dys Mgk. Therefore, we suggest that dysplastic features do not directly relate to apoptosis in MDS patients with FAB-RA except 5q-syndrome. To clarify the conclusion of our study, quantitative analysis of apoptosis by immunohistochemistry should be performed in the future studies.
